Paris, France, July 8th- 12th #ISPRM2018

“Ipsen has its strongest ever neuroscience presence at ISPRM 2018, demonstrating our strong focus on advancing the boundaries of neurotoxin research and our long-term commitment to patients and the neuroscience community, notably through medical education programs and symposiums. We will also disclose new data from the first-ever recombinant botulinum neurotoxin to be administered to humans, an area where we have the ambition to advance and unlock this innovative technology.”

Alexandre Lebeaut
MD, Executive Vice-President, R&D, Chief Scientific Officer, Ipsen


Ipsen announces clinical data to be presented at ISPRM demonstrating commitment to neurotoxin research and support for patients and the neuroscience community

ULIS Presentation

This year, we celebrate 10 years of success with the Upper Limb International Spasticity (ULIS) programme, which since its inception has involved people living with upper limb spasticity in 31 countries.

Oral Presentation

The driving force behind ULIS has always been to develop a comprehensive and person-centred approach to spasticity management that can be implemented internationally.

Satellite symposia

Symposium Tuesday July 10th 12:30 to 14:00
More patients or more goals: how does duration of response change clinical practice?


Follow the ISPRM 2018 activity on twitter #ISPRM2018


Meet us at Booth 1